PHARMACYCLICS, INC.

Inactive Instrument

Pharmacyclics, Inc. Stock

Equities

US7169331060

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2015	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
2015	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

Latest news about Pharmacyclics, Inc.

Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	15-05-06	RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	15-04-29	RE
Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	15-04-21	RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	15-04-21	RE
Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	15-04-08	RE
AbbVie : CEO defends Pharmacyclics deal to sceptical investors	15-03-05	RE
Wall Street closes up slightly ahead of jobs report	15-03-05	RE
AbbVie : CEO says new form of Humira could thwart generics	15-03-05	RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	15-03-05	RE
AbbVie : Biotech buys get pharma M&A off to flying start in 2015	15-03-05	RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	15-03-05	RE
Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	14-06-02	RE

Press releases Pharmacyclics, Inc.

Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	16-01-07	PU
Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	16-01-07	PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	16-01-07	PU
Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	16-01-07	PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	16-01-07	PU

More press releases

News in other languages on Pharmacyclics, Inc.

Wall Street se reprend un peu dans un climat d'attente	15-03-05
DJ Industrial : Wall Street se reprend un peu dans un climat d'attente	15-03-05
AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie	15-03-05
AbbVie : Wall Street quasiment stable après les chiffres du chômage	15-03-05
Apple : Les valeurs à suivre sur les marchés américains	15-03-05

Managers and Directors - Pharmacyclics, Inc.

Managers	Title	Age	Since
Wulff-Erik von Borcke CEO	Chief Executive Officer	-	15-04-30
Betty Chang CTO	Chief Tech/Sci/R&D Officer	-	13-07-08
Heow Tan CTO	Chief Tech/Sci/R&D Officer	65	12-04-30

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-1.78%	41.71B
LONZA GROUP AG	+47.70%	41.56B
MODERNA, INC.	+4.01%	39.74B
CELLTRION, INC.	-15.14%	25.61B
ICON PUBLIC LIMITED COMPANY	+3.16%	24.26B
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.93B
MEDPACE HOLDINGS, INC.	+24.76%	11.93B
UNITED THERAPEUTICS CORPORATION	+7.01%	10.91B

Other Biotechnology & Medical Research

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer